Working… Menu

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease (ESSENTIAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03949894
Recruitment Status : Recruiting
First Posted : May 14, 2019
Last Update Posted : November 14, 2019
Information provided by (Responsible Party):
Korea Otsuka Pharmaceutical Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2022